Incyte Corporation

This phase 3 study tested whether adding the immunotherapy drug retifanlimab (INCMGA00012) to standard platinum-based chemotherapy helps people with advanced non-small cell lung cancer live longer. The trial enrolled 583 patients who had not received prior treatment for metastati…

This phase 2 study tested a drug called retifanlimab, which helps the immune system attack cancer, either alone or combined with other targeted drugs. It enrolled 206 women with advanced or metastatic endometrial cancer that had worsened after platinum-based chemotherapy. The goa…

This Phase 3 trial tested whether combining pembrolizumab (an immunotherapy) with epacadostat (a drug that boosts the immune response) works better than standard drugs (sunitinib or pazopanib) for people with advanced kidney cancer that hasn't been treated before. The study enrol…

This early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for sig…

This study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic …

This phase 2 trial tested a cream called ruxolitinib (Opzelura) on 49 people with nonsegmental vitiligo affecting the genitals. Participants applied the cream twice daily for up to 48 weeks to see if it made the white patches less noticeable. The study measured success based on p…

This phase 2 trial tested an oral drug called povorcitinib in 136 adults with chronic spontaneous urticaria (hives and itching lasting months) that standard antihistamines couldn't control. Participants took either povorcitinib or a placebo for 12 weeks to see if the drug reduced…

This study tested whether adding the targeted drug ruxolitinib to standard chemotherapy helps children with a high-risk form of acute lymphoblastic leukemia (ALL). The trial involved 171 children and young adults aged 1 to 21. Researchers first found the best dose of ruxolitinib,…

This phase 3 trial tested the drug povorcitinib in 608 people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps and abscesses. Participants received either the drug or a placebo for 12 weeks, followed by a 42-week extension where eve…

This study tested whether adding itacitinib to the standard drug osimertinib is safe and effective for people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The trial involved 59 participants and was completed. The goal was to see if the combinat…

This phase 3 trial tested an oral drug called povorcitinib in 619 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful abscesses. Participants received either the drug or a placebo for 12 weeks, followed by a 42-week extension. The mai…

This study tested whether adding an experimental drug (epacadostat) to an immunotherapy (pembrolizumab) works better than standard chemotherapy for people with advanced head and neck cancer that has come back or spread. 89 adults took part. The main goal was to see how many patie…

This phase 2 trial tested a daily pill called pemigatinib in 47 people with a rare type of blood cancer caused by a specific genetic change (FGFR1 rearrangement). The drug aims to shrink or eliminate cancer cells by blocking a faulty protein. Participants took the drug in cycles,…

This Phase 3 trial tested whether adding the immunotherapy drug retifanlimab to standard chemotherapy (carboplatin and paclitaxel) helps people with advanced anal cancer that cannot be removed by surgery. The study enrolled 308 adults who had not received chemotherapy for their a…

This early-phase trial tested a new drug called INCA32459 in 46 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see how the body handles the drug. It is too early to know if the drug works, but the results will guide fut…

This study tested a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced melanoma or other solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could s…

This large Phase 3 study tested whether adding the drug itacitinib to standard steroids helps control acute graft-versus-host disease (GVHD) in people who had a stem cell transplant for blood cancer. About 439 participants received either itacitinib or a placebo along with steroi…

This phase 2 study tested the drug itacitinib in 4 people with myelofibrosis (a bone marrow disorder) who had already tried other treatments like ruxolitinib or fedratinib. The main goals were to check safety and find the right dose, and to see if it could shrink an enlarged sple…

This study tested a cream containing ruxolitinib on 241 adults with moderate atopic dermatitis (eczema) who had not gotten better with standard steroid creams. The goal was to see if the cream could improve skin clearing and reduce itching. The trial is now complete, and results …

This Phase 3 trial tested a cream called ruxolitinib (also known as Opzelura) in 190 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants applied the cream twice daily for 12 weeks. The main goal was to see if it could reduce itch b…

This Phase 3 trial tested a cream containing ruxolitinib in 204 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants applied the cream twice daily for 12 weeks. The main goal was to see if it reduced itch by at least 4 points on a 0…

This early-stage study looked at how food and two other drugs (itraconazole and carbamazepine) affect the way healthy adults process a new compound called INCB123667. Fifty-one participants took single doses of the compound under different conditions. The goal was to gather safet…

This study tested a new way to collect fluid from the skin using a tiny microneedle patch. Researchers compared samples from 20 healthy volunteers and people with eczema (atopic dermatitis) to see how much fluid could be collected and how well it was tolerated. The goal was to le…

This study looked at how a single dose of a drug called INCB123667 moves through and leaves the bodies of 9 healthy men. The drug was tagged with a tiny amount of radioactivity to track it in blood, urine, and stool. The goal was to understand how the drug is processed and elimin…

This completed phase 1 study looked at how three common drugs—an antifungal (itraconazole), an antibiotic (rifampin), and acid reducers (esomeprazole, famotidine)—change the way a new experimental drug (INCB161734) moves through the body. Sixty-three healthy adults aged 18 to 55 …

This early-stage study tested a new drug called INCB160058 in 137 healthy adults aged 18 to 55. The main goal was to check the drug's safety and how the body processes it, not to treat any disease. Participants took a single dose by mouth, and researchers monitored side effects a…

This completed Phase 1 study enrolled just 5 healthy men aged 35–55 to see how a single oral dose of the experimental drug INCB099280 (with a tiny radioactive label) is absorbed, broken down, and eliminated. Researchers measured radioactivity in urine and feces and checked drug l…